News & Analysis on Clinical Trial Services & Contract Research And Development
According to a recent report, projected sales for the worldwide DNA sequencing and proteomics markets are expected to rise at an average annual growth rate of 17.6 per cent from $7.8 billion (€5.9 billion) in 2004 to $17.5 billion in 2009.
Unisys has signed an agreement with Boston, US-based GenuOne to provide product tracking and authentication software to the healthcare and life sciences industries.
Serologicals has continued its acquisitive streak, buying the cell culture business Specialty Media from Sentigen Holding Corp, for $6.5m (€4.9m) in cash. The unit will be integrated into Serologicals' Chemicon subsidiary.
According to a latest study, only half of all patients receive appropriately administered antimicrobial infection medication within one hour of major surgery. The figure emphasises just how much patients are at risk from surgical site infections.
UK speciality oils supplier Croda International said sales to cosmetics and supplement customers rose 8 per cent last year, helped by expanded capacity in fish oil concentrates and new product launches.
Malvern Instruments of the UK has launched a new viscometer accessory for its Zetasizer Nano particle characterisation system that should improve the ability of the instrument to study emulsions and dispersions.
Researchers in the US have shed light on how tumours acquire resistance to kinase inhibitors. The discovery may help explain the acquired resistance observed in chemotherapy, which currently blights existing cancer treatments.
A pilot project aimed at combating pharmaceutical fraud using a combination of radiofrequency identification (RFID) tagging and bar coding, set up by UK firm Aegate last November, has come to a close and the results should be made available on 14 March.
Novartis, the Swiss pharmaceutical giant has acquired two companies as it aims to expand its generics drug portfolio and increase its presence in the generics sector. The strategic move is expected to make Novartis the world's top seller of branded drugs.